Together ⋯ to take care: Multidisciplinary management of hepatitis c virus treatment in randomly selected drug users with chronic hepatitis

Journal of Addiction Medicine

Volumn 4, Issue 4, 2010, Pages 223-232

  Curcio, Fabio ^a   Di Martino, Filomena ^b   Capraro, Clara ^a   Angelucci, Federico ^c   Bulla, Fabio ^b   Caprio, Nunzio ^b   Cascone, Angela ^b   D'Ascoli, Gelsomina ^a   Focaccio, Flora ^a   Gaveglia, Michela ^a   Longobardo, Anna ^a   Martini, Salvatore ^b   Masucci, Salvatore ^a   Morra, Alessandra ^c   Pasquale, Giuseppe ^b   Pisapia, Raffaella ^b   Plenzik, Marinella ^a   Veneruso, Ciro ^a   Villano, Giuseppina ^a   Russo, Manlio ^c   De Rosa, Giuseppe ^a   Filippini, Pietro ^b   more..

^a UO SERT DS 31 ASL Napoli 1 Centro   (Italy)

^b DAI Malattie Infettive e Medicina Interna SUN ^*  (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Addiction; HCV infection; HCV therapy; Healthcare management; Intravenous drug users; Peg interferon; Ribavirin

Indexed keywords

EID: 79954470621     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181cae4d0     Document Type: Article

References (21)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000.
2. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004;39:1540-1543. (Pubitemid 39518222)
3. Backmund M, Meyer K, Von Zielonka M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193. (Pubitemid 32591499)
4. Brener L, von Hippel W, Kippax S. Prejudice among health care workers toward injecting-drug users with hepatitis C: Does greater contact lead to less prejudice? Int J Drug Policy 2007;18:381-387. (Pubitemid 47374500)
5. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40(suppl 5):S276.
6. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211-217.
7. Farley J, Vasdev S, Fischer B, et al. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005;95:1737-1739. (Pubitemid 41369041)
8. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008;93:141-147. (Pubitemid 350245718)
9. Guadagnino V, Trotta MP, Montesano F, et al. Effectiveness of a multidisciplinary standardised management model in treatment of chronic hepatitis C in drug users engaged in detoxification programmes. Nocchiero Study Group. Addiction 2007;102:423-431. (Pubitemid 46239368)
10. Hopwood M, Treloar C. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. Int J Drug Policy 2007;18:374-380. (Pubitemid 47374499)
11. Krook AL, Stokka D, Heger B, et al. Hepatitis C treatment of opioid dependants receiving maintenance treatment: Results of a Norwegian pilot study. Eur Addict Res 2007;13:216-221. (Pubitemid 47414339)
12. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124. (Pubitemid 38868930)
13. Novick DM, Kreek MJ. Critical issues in treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008;103:905-918. (Pubitemid 351703476)
14. Robaeys G, De Bie J, Wichers MC, et al. Early prediction of major depression in chronic hepatitis C patients during peg-interferon α-2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J Gastroenterol 2007;13:5736-5740. (Pubitemid 350120227)
15. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction 2004;99:1167-1175. (Pubitemid 39215278)
16. Sylvestre DL. Hepatitis C treatment in drug users: Perception versus evidence. Eur J Gastroenterol Hepatol 2006;18:129-130.
17. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007;19:741-747. (Pubitemid 47266701)
18. Sylvestre DL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005;29:159-165. (Pubitemid 41383828)
19. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003;98:2281-2288. (Pubitemid 37305371)
20. Wagner GJ, Ryan GW. Hepatitis C virus treatment decision-making in the context of HIV co-infection: The role of medical, behavioral and mental health factors in assessing treatment readiness [Section V: Treatment, treatment services and prevention]. AIDS 2005;19(suppl 3): S190-S198. (Pubitemid 41682187)
21. Zehnter E, Mauss S, Boeker K, et al. Potential relevance of rapid viral response for svr and optimization of treatment of hepatitis C (CHC) with peginterferon alfa-2a and ribavirin (RBV). 42nd Annual Meeting of the European Association for the Study of the Liver. April 11-15, 2007, Barcelona, Spain.